Introduction and objectives Acute pulmonary embolism (PE) is the third most frequent acute
cardiovascular syndrome. Systemic thrombolysis is the treatment of choice in patients with …

Background: While the primary therapy for most patients with a pulmonary embolism (PE)
consists of anticoagulation, the efficacy of thrombolysis relative to standard therapy remains …

Purpose Current literature on clinical controversies surrounding the use of thrombolytic
agents in patients with intermediate-risk pulmonary embolism (PE) is reviewed. Summary …

While systemic intravenous thrombolysis decreases mortality in patients with high-risk
pulmonary embolism (PE), it clearly increases haemorrhagic risk. There are many …

Aim and Methods: We aimed to study the clinical data and outcome of patients admitted in
our center with acute pulmonary embolism (PE) over a 5-year period from May 2013 to April …

Objective Although systemic thrombolysis (ST) is the standard of care in the treatment of
high-risk pulmonary embolism (PE), large variations in real-world usage exist, including its …

Acute pulmonary embolism (PE) is a life-threatening event with an estimated mortality rate
ranging between 7 and 11%[1]. Both current European Society of Cardiology (ESC) and …

Aims Pulmonary embolism (PE) is the third most common cardiovascular cause of death;
systemic thrombolysis is potentially lifesaving treatment in patients presenting with …

The early mortality in pulmonary embolism (PE) is largely predicted by the associated
cardiovascular response, with progressive right ventricular failure, hypotension, shock, and …

Introduction Reperfusion therapy is generally recommended in acute high-risk pulmonary
embolism (HR-PE), but several population-based studies report that it is underused. Data on …